Exact Sciences Corporation Stock Mexican S.E.
Stocks
EXAS *
US30063P1057
Biotechnology & Medical Research
| Market Cap | 20.03B 350B 17.58B 16.52B 15.11B 28.23B 1,918B 28.44B 198B 76.94B 978B 75.2B 73.56B 3,171B | P/E 2024 |
-10.1x | P/E 2025 | -92.2x |
|---|---|---|---|---|---|
| Enterprise Value | 21.6B 377B 18.95B 17.82B 16.29B 30.44B 2,069B 30.67B 214B 82.97B 1,055B 81.1B 79.32B 3,420B | EV / Sales 2024 |
4.4x | EV / Sales 2025 | 6.42x |
| Free-Float |
98.24% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Exact Sciences Corporation
| 1 day | -15.23% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.23% | +9.18% | - | - | 20.03B | |
| +0.64% | +2.05% | +382.31% | +123.74% | 4.62B | |
| +2.04% | -0.32% | +122.00% | +460.24% | 4.45B | |
| +4.18% | +11.66% | +38.62% | +101.60% | 3.52B | |
| +8.99% | +8.84% | +292.30% | +673.30% | 2.81B | |
| +2.50% | +22.28% | -7.77% | -15.52% | 2.52B | |
| -0.51% | +6.59% | +48.11% | - | 1.69B | |
| -0.58% | +4.78% | +29.52% | +61.14% | 1.13B | |
| -0.47% | +0.89% | +169.67% | -21.13% | 1.1B | |
| +5.08% | +4.75% | -20.77% | +84.39% | 625M | |
| Average | +0.67% | +4.66% | +117.11% | +183.47% | 2.5B | |
| Weighted average by Cap. | -5.78% | +4.96% | +157.31% | +237.28% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.76B 48.22B 2.42B 2.28B 2.08B 3.89B 264B 3.92B 27.34B 10.6B 135B 10.36B 10.13B 437B | 3.25B 56.76B 2.85B 2.68B 2.45B 4.58B 311B 4.61B 32.18B 12.47B 159B 12.19B 11.93B 514B |
| Net income | -1.03B -17.98B -903M -849M -776M -1.45B -98.56B -1.46B -10.2B -3.95B -50.25B -3.86B -3.78B -163B | -208M -3.63B -183M -172M -157M -293M -19.92B -295M -2.06B -799M -10.16B -781M -764M -32.93B |
| Net Debt | 1.74B 30.37B 1.53B 1.43B 1.31B 2.45B 166B 2.47B 17.22B 6.68B 84.87B 6.53B 6.38B 275B | 1.57B 27.44B 1.38B 1.3B 1.18B 2.21B 150B 2.23B 15.56B 6.03B 76.68B 5.9B 5.77B 249B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
